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Abstract
Background: In recent years the ‘‘noninferiority’’ trial has emerged as the new standard design for HIV drug development
among antiretroviral patients often with a primary endpoint based on the difference in success rates between the two
treatment groups. Different statistical methods have been introduced to provide confidence intervals for that difference.
The main objective is to investigate whether the choice of the statistical method changes the conclusion of the trials.
Methods: We presented 11 trials published in 2010 using a difference in proportions as the primary endpoint. In these trials,
5 different statistical methods have been used to estimate such confidence intervals. The five methods are described and
applied to data from the 11 trials. The noninferiority of the new treatment is not demonstrated if the prespecified
noninferiority margin it includes in the confidence interval of the treatment difference.
Results: Results indicated that confidence intervals can be quite different according to the method used. In many situations,
however, conclusions of the trials are not altered because point estimates of the treatment difference were too far from the
prespecified noninferiority margins. Nevertheless, in few trials the use of different statistical methods led to different
conclusions. In particular the use of ‘‘exact’’ methods can be very confusing.
Conclusion: Statistical methods used to estimate confidence intervals in noninferiority trials have a strong impact on the
conclusion of such trials.
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Introduction
The efficacy of antiretroviral therapy for treatment of HIV-1
infection has improved steadily since the advent of potent
combination therapy in 1996 [1]. Introduction of drugs that offer
new mechanisms of action with improved safety profiles and lower
pill counts has led to highly potent combination, the so-called
Highly Active AntiRetroviral Therapy (HAART) [1,2]. Most
recent HIV clinical trials reflect such an improvement since, in
naı ¨ve patients, rates of HIV RNA below 50 copies/mL over 80–
85% have been reported [3,4,5] and promising results were found
in treatment-experienced patients [6].
Most of the earlier developments have been made by designing
and analysing superiority trials. However, high levels of efficacy
and inherent difficulty in the use of combinations of triple-drug
makes difficult new improvement. Studies of treatment naı ¨ve
patients indicate that addition of a fourth drug may provide only
small incremental benefits [7]. Moreover, failure of the primary
endpoint, usually HIV RNA suppression below 50 copies/mL at
week 48, is often due to ‘therapeutic failure’ or lost to follow-up
rather than genuine virologic failure. Indeed, use of the so-called
TLOVR (time to loss of virologic response) implied that patients
who prematurely discontinued the study or modified their study
treatment before week 48 are considered as failures [8].
Consequently, in most of the HIV clinical trial using the TLOVR
algorithm one observed at least 5–10% of ‘non-virologic’ failures.
HIV noninferiority trial has emerged as the new standard
design for HIV drug development among antiretroviral-naı ¨ve
individuals [9,10] but also in treatment experienced patients
[11,12,13]. These trials aim to show that a new treatment (new
combination) is not worse than the current standard by more than
a prespecified margin, the so-called noninferiority margin. Design
and interpretation of these trials have been already discussed and
criticized in the HIV area [14]. In the analysis and interpretation
of studies of non-inferiority at least five factors must be carefully
considered to ensure the validity of the study: selection of non-
inferiority margin, number of patients needed for the study,
control of study sensitivity, definition of population analysis and
ethical justification.
In this work, we present some recent HIV noninferiority trials
designed for naı ¨ve and treatment experienced patients. Results,
hypotheses and the use of the different sets of patients are
discussed. The different statistical methods used in these trials are
briefly described. A reanalysis of these data with the different
methods is presented and discussed. The main objective is to
investigate whether the choice of the statistical method influence
the conclusion of the trials. The choice of the ‘best’ method is
discussed in the last section.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e22871Materials and Methods
Noninferiority trials
The objective of this work is to investigate the impact of the
statistical analysis currently used on results of recent HIV trials.
Criteria to select the HIV noninferiority studies were the
following: results published or presented in 2010, inclusion of
HIV-infected adult patients (.18 years), use of a primary endpoint
based on a difference in proportions reflecting efficacy, and not use
of a stratified analysis. In trials using a difference in proportions as
primary endpoint, the proportion of response (number of patients
with response out of the total number of patients) is provided in
each arm. Such information is sufficient to compute the difference
in proportions, confidence intervals and tests with any statistical
method. It is then easy to recover sufficient information to
reanalyze data with another method that the one used in the
original publication.
Population sets and analysis
For superiority trials, the full analysis set - intention-to-treat
(ITT) population - is recommended because it tends to avoid over-
optimistic estimates of efficacy resulting from a per protocol (PP)
analysis, since non-compliers included in the full analysis set will
generally diminish the estimated treatment effect [15,16]. Thus, it
is often said that the ITT analysis tends to dilute the treatment
difference [17] even though not always [18]. If a dilution of the
treatment effect is observed, in noninferiority trials, the ITT
analysis will increase the risk of falsely claiming noninferiority [15].
Poor adherence, imprecise measurements and processes increase
the variability and mask the differences between treatments
increasing again the likelihood of falsely accepting non-inferiority.
In a noninferiority trial we considered that ITT and PP analyses
have equal importance and their use should lead to similar
conclusions for a robust interpretation [15,16]. A reason, however,
to consider the ITT analysis as the primary analysis is that the
sample size is computed for the ITT analysis since it seems
impossible to estimate how many patients will be excluded from
the PP population. Nevertheless one difficulty is the wide range of
distinct PP analysis or non-ITT analyses.
Statistical methods
Although a modified hypothesis testing framework exists,
reporting of the noninferiority trials is often preferred using the
confidence interval approach. Most methods, however, provide
equivalently a test statistic and a corresponding confidence interval
of the observed treatment difference. Let p1 and p2 represent the
true proportions of patients in success in patients receiving the new
treatment and the reference treatment (control group). We are
interested in the difference, p12p2=D. Null hypothesis for the
noninferiority test is H0: D#DL versus the alternative hypothesis
H1: D.DL where DL is the pre-specified noninferiority margin
[19,20]. Estimates of p1 and p2 are noted p1 and p2 that
correspond to the observed proportions of success in the new
treatment and control groups, respectively, with d=p 12p2, The
general framework for the test statistic z is based on z=(d+DL)/
se(d) where se(d) is the standard error of the observed difference.
The most simple and popular method, hereafter called the Wald
method, is to estimate se(d)b y( p 1 (1- p1)/n1+p2 (1- p2)/n2)
1/2 using
the normal approximation [19]. The corresponding confidence
interval of the observed treatment difference is given by d6Za/2
se(d) where Za/2 is the upper (a/2)
th quantile of the standard
normal distribution. In this method there is a complete
concordance, for both a given noninferiority margin and type I
error, in the conclusion based on the lower limit of the d’s
confidence interval or on the p value provided by the z statistic.
Four other methods, however, were applied in the analyses of
those recent HIV noninferiority trials; Farrington and Manning
(FM), Exact, Newcombe, and Miettinen and Nurminen (MN)
methods [21,22,23,24]. The FM approach is based on the statistic
z described above but with a different estimate of the standard
error. As pointed out by Farrington and Manning, the MN statistic
is identical to FM except for a term (N-1)/N which is negligible in
large samples [22]. The Newcombe method is based on the Wilson
score method for the single proportion, without continuity
correction [24]. The term ‘exact’ should be used with cautious
since different methods have been proposed to compute ‘exact’
confidence intervals for a difference of proportions. The Exact
approach used in the PROGRESS study was proposed by Chan
and Zhang (CZ) [18,21] and provides exact unconditional
confidence limits that guarantee the level of coverage probability
(calculated using StatExact). But, for instance, the method of
Santner and Snell (SS) was used in a previous version of StatExact
and is available in SAS version 9.2 [25]. More details of those
methods can be found in the corresponding articles.
Results
Eleven noninferiority trials were selected from criteria described
above and table 1 summarizes their main characteristics
[6,9,10,11,12,13,26,27,28,29]. EASIER results were published in
2009 but the study was included because both it involved a small
sample size and provided a treatment difference very closed to 0.
Such a situation may potentially provide quit different confidence
intervals estimates. Studies are ordered by sample size from trials
enrolling less than 100 patients per arm to 300 patients per arm.
Primary endpoint was mainly achievement of an HIV-RNA ,50
copies/mL measured at week 48 of follow-up although few studies
used a slightly different endpoint.
Clinical and statistical hypotheses
Hypotheses of success rates and power were either found in
original articles or provided by investigators after request. For one
trial, however, information on success rates and power were
missing. Hypotheses of success rates varied from 70% to 96% and
should be consistent with data from previous studies using both
similar treatment regimen and population of patients. In some
cases, however, it is difficult to anticipate success or failure rates
with a new combination therapy or with a current combination
but in a new population of patients.
Most of the noninferiority margin was fixed at 12% or around
12% (two studies had a 10% margin and one a 12.5% margin).
The PROGRESS study used an unconventional 20% margin to
investigate the efficacy of a new combination (lopinavir/r+ralte-
gravir) [9]. The power is one of the key points of a study and
summarized by itself most of the statistical hypotheses. Despite a
large noninferiority margin, the PROGRESS study has a 90%
power. Then a margin of 12% in the PROGRESS study, with the
same rates of success and sample size (n=100/arm), would
approximately lead to a low power of 50%.
Another key point is the type I error (a significance level) or
equivalently the level of the confidence interval (CI). A 1-sided
a=0.025 corresponds to a 2-sided 95% CI. MONOI and
KALESOLO studies used a 2-sided 90%. There is a wide use of
a 2-sided 95%CI although a 2-sided 90% CI is deemed acceptable
for the noninferiority hypothesis test [15]. In the two studies using
a 2-sided 90%CI, a monotherapy with a ritonavir-boosted
protease inhibitor was compared with a triple-drug regimen
Reanalysis of Recent HIV Trials
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single drug cannot be better than a triple-drug regimen justifying
the use of a 1-sided a=0.05. Importantly, MONET and MONOI
had equivalent power because in MONOI study the use of a
smaller 2-sided CI (90%) is balanced by a smaller noninferiority
margin (10%) compared with MONET that used a 95% 2-sided
CI but with a 12% margin [11,12].
Population sets and analysis
The MONET study excluded from the PP analysis mainly
patients on the basis of violation of inclusion criteria, while the
MONOI study excluded patients on the basis of major protocol
violations, including violation of inclusion criteria and violation of
the protocol post randomization [11,12]. For instance, in the
MONOI study while discontinuation was a cause of failure in the
definition of the primary endpoint, patients who discontinued
study treatment without virologic failure or severe adverse event
were excluded from the PP population [12]. The KALESOLO
study used a ‘switch included’ sensitivity analysis where all patients
who intensified their antiretroviral treatment in the monotherapy
arm were considered as success if they had an HIV-1 RNA ,50
copies/ml at week 48 [28]. All other studies used an ‘on-treatment’
analysis considering only patients still receiving the assign
treatment or an observed analysis which is quit similar although
few distinctions can be found in the way missing data were
handled.
Results of the seven trials considering a non-ITT analysis in
addition to the ITT analysis are displayed in Figure 1. Most of the
trials provided very similar results between ITT and non-ITT
analyses. KALESOLO exhibits an important difference between
the ITT and the switch-included analysis but the latter analysis is
special and had received criticisms [30]. One can be somewhat
puzzled by results of the NCT00162643 study for a noninferiority
design that exhibit a strong benefit of the new treatment group like
a superiority trial.
Confidence intervals estimates
The four methods, briefly described above, were then applied to
data of the 11 trials (tables 2 and 3). As discussed above results
based on the MN method were very similar to those provided by
the FM method and are not displayed. Original results published
or presented are indicated in bold. As expected, the four methods
provided more different confidence intervals with 100 patients
randomized per arm rather than with 300 patients per arm. In the
EASIER study, the Wald method estimated the smaller confidence
interval while the FM method provided the larger one. Then,
although the conclusion of this study is not affected by the choice
of the method, those methods led to very distinct confidence
intervals. The sample size, however, is not the only factor that
influenced confidence interval estimates. There is more discrep-
ancy between the confidence interval estimates in the MONOI
study than in the NCT00162643 study. The four methods
provided almost similar confidence intervals in studies involving
more than 200 patients per treatment arm.
Conclusion of the trials
Values in italic in Tables 2 and 3 indicate the method leading to
inconclusive results, i.e., the noninferiority could not be demon-
strated. Fortunately, a complete agreement of conclusions was
mainly observed with the use of the four distinct methods except in
two situations. In the MONOI study, the PP analysis using the
Wald method, as planned in the protocol, demonstrated the
noninferiority of the darunavir/ritonavir monotherapy to dar-
unavir/r triple therapy but the three other methods were
inconclusive. Similarly, in the Switchmrk 2 study the noninfer-
iority of a raltegravir-based regimen to a lopinavir/ritonavir-based
regimen was demonstrated with the Wald method but not with the
three other methods.
Widths of confidence intervals of ITT versus PP: an
artifical example
The reason of a larger confidence interval for the ITT analysis
compared with the PP analysis is given in Table 4. Table 4
illustrates how sample sizes and level of success rates, for a fixed
treatment difference, impact the width of the confidence interval.
We computed the width of the confidence interval with the Wald
method in different situations where d=25%. The width of the
confidence interval is strongly affected by the levels of success rates
in the two groups. For example, it changes from 0.103 when
p1=90% vs. p2=95% to 0.196 when p1=50% vs. p2=55%
(Table 4). Potential difference between ITT and PP analyses can
be illustrated with the following hypothetical trial. Consider a trial
with d=25% in both ITT and PP analyses but with a success rate
of 85% and 90% in the control group in the ITT and PP
Table 1. Descriptive information on 11 recent HIV noninferiority trials.
Studies Patients Comparison Sample size Hypothesis Margin Power 2-sided CI Method
EASIER trt-exp RAL vs. ENF 85 vs. 84 p1=p2=96% 10% 80% 95% Farrington and
Manning
KALESOLO trt-exp LPV/r alone vs. HAART 87 vs. 99 p1=p2=90% 12% 80% 90% Wald
NCT00162643 naive EFV vs. LPV/r 95 vs. 94 12% 95% Wald
PROGRESS naive RAL/LPV/r vs. TDF/FTC/LPV/r 101 vs. 105 p1=p2=75% 20% 90% 95% Exact CZ
MONOI trt-exp DRV/r alone vs. DRV/r-regimen 112 vs. 113 p1=p2=90% 10% 80% 90% Wald
MONET trt-exp DRV/r alone vs. DRV/r-regimen 123 vs 123 p1=p2=90% 12% 80% 95% Wald
SPIRAL trt-exp RAL vs. PI/r 139 vs. 134 p1=p2=85% 12.5% 80% 95% Newcombe
Switchmrk 1 and 2 trt-exp RAL vs LPV/r 172 vs. 174 175 vs. 178 p1=p2=87.5% 12% 90% 95% Miettinen and
Nurminen
ODIN trt-exp DRV/r qd vs. DRV/r bid 294 vs. 296 p1=p2=70% 12% 90% 95% Wald
M06-802 trt-exp LPV/r qd vs. LPV/r bid 300 vs. 299 p1=p2 12% .80% 95% Wald
Trt-exp: treatment experienced.
doi:10.1371/journal.pone.0022871.t001
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confidence interval is 0.149, with n1=n 2=190 in the PP analysis,
corresponding to a 5% loss of patients, the width of the CI is
0.133, increasing then probability of demonstrating the noninfer-
iority with a similar treatment difference (Table 4). Similar trends
were found with the three other statistical methods.
Widths of confidence intervals of the 11 trials
In general, the Wald method is known as being conservative,
i.e., producing smaller width of confidence intervals compared
with other methods. Table 5 demonstrated, however, than the
Wald method did not estimates systematically shortest confidence
intervals. Considering the 18 ITT and non-ITT analyses the Wald
Figure 1. Difference in success rates with confidence intervals in 9 trials presenting both an ITT and a non-ITT analyses.
doi:10.1371/journal.pone.0022871.g001
Table 2. Results of 6 HIV noninferiority trials.
Confidence intervals
Studies Analysis Margin Results d Wald Exact CZ Newcombe FM
EASIER ITT 210% 98.8% vs. 98.8% 0.01% 23.3% to 3.3% 25.6% to 5.7% 25.3% to 5.4% 26.7% to 6.8%
EASIER OT 210% 98.8% vs.100% 21.22% 23.6% to 1.2% 27.3% to 3.4% 26.6% to 3.4% 28.1% to 5.6
KALESOLO ITT 212% 83.9% vs. 87.9% 23.97% 212.4% to 4.5% 214.7% to 6.3% 212.7% to 4.5% 212.7% to 4.8%
KALESOLO Switch included 212% 90.8% vs. 87.9% 2.93% 24,5% to 10.4% 27.0% to 12.3% 24.8% to 10.5% 25.4% to 11.3%
NCT00162643 ITT 212% 70.5% vs. 53.2% 17.33% 3.7% to 31% 3.3% to 30.7% 3.5% to 30.3% 3.5% to 31.1%
NCT00162643 OT 212% 85.9% vs. 61.7% 24.2% 11.1% to 37.3% 10.4% to 37.1% 10.6% to 36.6% 10.2% to 38.1%
PROGRESS ITT 220% 83.2% vs. 84.8% 21.6% 211.6% to 8.4% 212.0% to 8.8% 211.8% to 8.5% 212.2% to 9.0%
MONOI ITT 210% 87.5% vs. 92.0% 24.54% 211.2% to 2.1% 213.0% to 4.1% 211.4% to 2.2% 211.5% to 2.5%
MONOI PP 210% 94.1% vs. 99.0% 24.9% 29.1% to 20.8% 211.4% to 0.2% 210.1% to 20.6% 210.1% to 0.3%
MONET ITT 212% 84.3% vs. 85.3% 21.0% 29.8% to 7.8% 210.1% to 8.3% 29.9% to 7.9% 210.1% to 8.1%
MONET PP 212% 86.2% vs. 87.8% 21.6% 210.0% to 6.8% 210.4% to 7.4% 210.2% to 6.9% 210.4% to 7.1%
ITT: intent-to-treat, PP, per-protocol, OT on-treatment.
Original results are bolded and values in italic indicate inconclusive results (noninferiority not demonstrated).
doi:10.1371/journal.pone.0022871.t002
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the Newcombe method in 4 analyses, and the FM in one. The
Newcombe method estimated shortest confidence intervals when d
was very large (d.17%). Largest confidence intervals were
estimated by the FM method in 8 analyses and by the Exact
(CZ) method in 10 analyses.
Exact methods
Table 6 illustrates the difference in ‘exact’ confidence interval
between the CZ and the SS methods. EASIER provided the most
extreme situation since the confidence interval changes from
[25.6; 5.7%] with the CZ method to [215.0%; 15.0%] with the
SS method. Thus, the use of the SS method would lead to
Table 3. Results of 5 HIV noninferiority trials.
Confidence intervals
Studies Analysis Margin Results d Wald Exact CZ Newcombe FM
SPIRAL ITT 212.5% 89.2% vs. 86.6% 2.6% 25.1% to 10.4% 25.5% to 10.9% 25.2% to 10.6% 25.6% to 10.9%
SPIRAL OT 212.5% 96.9% vs. 95.1% 1.8% 23.9% to. 7.5% 23.7% to 7.6% 23.5% to 7.5% 25.0% to 8.6%
Switchmrk 1 ITT 212% 80.8% vs. 87.4% 26.54% 214.2% to 1.14% 214.4% to 1.3% 214.3% to 1.2% 214.3% to 1.2%
Switchmrk 2 ITT 212% 88.0% vs. 93.8% 25.82% 211.8% to 0.15% 212.2% to 0.3% 212.1% to 0.3% 212.2% to 0.5%
ODIN ITT 212% 72.1% vs. 70.9% 1.2% 26.1% to 8.5% 26.2% to 8.6% 26.1% to 8.4% 26.1% to 8.5%
M06-802 ITT 212% 55.3% vs. 51.8% 3.5% 24.5% to 11.5% 24.6% to 11.6% 24.5% to 11.4% 24.4% to 11.4%
M06-802 Observed data 212% 76.0% vs. 72.2% 3.8% 24.3% to 11.9% 24.4% to 12.1% 24.3% to 11.9% 24.3% to 12.0%
ITT: intent-to-treat, PP, per-protocol, OT on-treatment.
Original results are bolded and values in italic indicate inconclusive results (noninferiority not demonstrated).
doi:10.1371/journal.pone.0022871.t003
Table 4. Computation of the width of 95% confidence interval according to different sample size and success rates for a fixed
treatment difference of 25%.
Width of 95% confidence interval for d=25%
ITT PP
N1=N2 N1=N2
p2 p1 200 190 180 170 160 150
0.95 0.90 0.103 0.105 0.108 0.111 0.115 0.119
0.90 0.85 0.129 0.133 0.136 0.140 0.145 0.149
0.85 0.80 0.149 0.152 0.157 0.161 0.166 0.172
0.80 0.75 0.163 0.168 0.172 0.177 0.183 0.189
0.75 0.70 0.175 0.179 0.184 0.190 0.195 0.202
0.70 0.65 0.183 0.188 0.193 0.199 0.205 0.212
0.65 0.60 0.190 0.194 0.200 0.206 0.212 0.219
0.60 0.55 0.194 0.199 0.204 0.210 0.216 0.223
0.55 0.50 0.196 0.201 0.206 0.212 0.219 0.226
N1=N2 N1=N2
p2 p1 100 95 90 85 80 75
0.95 0.90 0.145 0.149 0.153 0.158 0.163 0.168
0.90 0.85 0.183 0.188 0.193 0.198 0.204 0.211
0.85 0.80 0.210 0.216 0.222 0.228 0.235 0.243
0.80 0.75 0.231 0.237 0.244 0.251 0.258 0.267
0.75 0.70 0.247 0.254 0.261 0.268 0.276 0.285
0.70 0.65 0.259 0.266 0.273 0.281 0.290 0.299
0.65 0.60 0.268 0.275 0.283 0.291 0.300 0.309
0.60 0.55 0.274 0.281 0.289 0.297 0.306 0.316
0.55 0.50 0.276 0.284 0.291 0.300 0.309 0.319
ITT: intent-to-treat, PP, per-protocol.
doi:10.1371/journal.pone.0022871.t004
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inconclusive for the MONET and Swithmrk 2 studies. Large
differences between those two methods were also found with trials
including more than 100 patients per arm (SPIRAL). The exact SS
method provided the largest confidence intervals in all situations
explored in Tables 2 and 5.
Discussion
This work investigated the impact of the statistical methods used
in the analysis of HIV noninferiority trials. An optimistic view may
consider that, from the 18 datasets (trial/set of population)
analyzed by 4 different statistical methods, different conclusion
of the results were draw in only 2 occasions. One remark,
however, than in some datasets the different methods assessed very
distinct confidence intervals. Conclusions were not altered by
those different confidence intervals due to the point estimate of the
treatment difference. It is obvious that an observed treatment
difference far from the noninferiority margin will generally lead to
demonstrate noninferiority whatever the method used. In the two
datasets with discordant conclusions, the observed treatment
differences were 24.9% and 25.82% corresponding to the
midpoint between 0 and the noninferiority margin chosen.
The MONOI study provides an interesting situation since the
PP analysis concluded to the noninferiority while the ITT was
inconclusive. As discussed above, it is often admitted that the ITT
analysis tends to dilute the treatment difference and then may lead
to erroneously conclude of noninferiority for a drug that is truly
inferior to the active control groups among compliers [15]. A
general idea is also that the width of the confidence interval of the
treatment difference for the PP analysis is larger than the ITT
analysis, due to smallest sample sizes. Although it has be noted that
Table 5. Width of confidence intervals for the 11 HIV noninferiority trials according to the different statistical methods.
Width of confidence intervals
ITT non-ITT
Studies Wald Exact CZ Newcombe FM Wald Exact CZ Newcombe FM
EASIER 0.065 0.112 0.106 0.135 0,048 0,107 0,100 0,137
KALESOLO 0.169 0.210 0.171 0.175 0,149 0,193 0,153 0,167
NCT00162643 0.273 0.274 0.268 0.276 0.262 0.268 0.261 0.279
PROGRESS 0.201 0.208 0.203 0.212
MONOI ITT 0.132 0.171 0.136 0.137 0.098 0.116 0.106 0.104
MONET ITT 0.176 0.184 0.178 0.181 0.168 0.178 0.172 0.175
SPIRAL 0.155 0.163 0.158 0.165 0,098 0,113 0,111 0,136
Switchmrk 1 0.154 0.157 0.155 0.155
Switchmrk 2 0.119 0.125 0.127 0.127
ODIN 0.146 0.147 0.145 0.146
M06-802 0.160 0.161 0.159 0.159 0,162 0,165 0,162 0,163
ITT: intent-to-treat.
Smaller value is underlined and larger value is bolded.
doi:10.1371/journal.pone.0022871.t005
Table 6. Comparison between two exact methods (CZ, Chang and Zhang and SS, Santner and Snell) applied to data from the 11
HIV noninferiority trials.
Studies Analysis Exact CZ Exact SS Studies Analysis Exact CZ Exact SS
EASIER ITT 25.6% to 5.7% 215.0% to 15.0% SPIRAL ITT 25.5% to 10.9% 29.3% to 14.6%
EASIER OT 27.3% to 3.4% 214.6% to 17.0% SPIRAL OT 23.7% to 7.6% 210.6% to 14.3%
KALESOLO ITT 214.7% to 6.3% 218.3% to 10.5%
KALESOLO Switch included 27.0% to 12.3% 211.5% to 17.2%
NCT00162643 ITT 3.3% to 30.7% 2.7% to 30.8% Switchmrk 1 ITT 214.4% to 1.3% 217.1% to3.9%
NCT00162643 OT 10.4% to 37.1% 8.4% to 38.6% Switchmrk 2 ITT 212.2% to 0.3% 216.1% to 4.8%
PROGRESS ITT 212.0% to 8.8% 215.1% to 12.2% ODIN ITT 26.2% to 8.6% 26.9% to 9.2%
MONOI ITT 213.0% to 4.1% 217.4% to 8.6% M06-802 ITT 24.6% to 11.6% 24.7% to 11.5%
MONOI PP 211.4% to 0.2% 218.9% to 9.3% M06-802 Observed data 24.4% to 12.1% 25.5% to 13.0%
MONET ITT 210.1% to 8.3% 213.4% to 11.1%
MONET PP 210.4% to 7.4% 214.4% to 11.2%
ITT: intent-to-treat, PP, per-protocol, OT on-treatment.
Values in italic indicate inconclusive results (noninferiority not demonstrated).
doi:10.1371/journal.pone.0022871.t006
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larger variances and then to larger confidence intervals [18]. In the
MONOI study, it is difficult to consider a dilution of the treatment
effect since the two analyses provide very concordant results
(24.5% vs. 24.9%). Nevertheless, the ITT analysis failed to
demonstrate noninferiority, whereas the PP analysis showed
noninferiority.
The regulatory agencies provide guidelines covering the
statistical principles for clinical trials [16] including the choice of
the noninferiority margin [31] and the points to consider on
switching between superiority and non-inferiority [32]. The
approach based on confidence intervals for difference in
proportions is accepted but no specific statistical methods are
recommended. It is expected that the full analysis set and the per
protocol set lead to the same conclusions to increase confidence in
the trial results [16]. In the MONOI study, however, treatment
differences estimates in the ITT and PP anlyses were almost
similar whereas leading to difference conclusions. Superiority trials
may not serve to demonstrate non-inferiority and the main
conclusion of non-inferiority trials should be stated whether the
non-inferiority is demonstrated or not. A recent HIV equivalence
trial is confusing since for the two pairwise comparisons the two
upper limits of the 95% CI were greater than the prespecified
margin whereas the authors concluded that the two regimens had
‘similar’ antiviral activity [33].
The choice of the noninferiority margin is a key point and
should be based upon a combination of statistical reasoning and
statistical judgement [31]. The link with statistical hypotheses was
best illustrated with the PROGRESS study that provides a similar
power than the ODIN study with a much larger margin (20% vs.
12%). In general, it is admitted that the margin should be smaller
than the clinically relevant effect [15,34]. The margin should also
be linked with the severity of the primary endpoint. In the HIV
trials, mortality and clinical endpoint are rarely used since 1997
and the consequence of virologic/treatment failure as primary
endpoint in current HIV trials is a treatment modification. In most
cases, patients who changed all or one compound of their regimen
are subsequently in therapeutic success with HIV-1 RNA ,50
copies/mL [11,12]. One can suspect than a margin lower than
10% would be used with a primary endpoint based on mortality or
occurrence of serious clinical events. Noninferiority trials accept
that a new treatment should be worse than the standard by an
amount less than the prespecified margin on the premise that it has
some other advantage (lower toxicity, greater ease of administra-
tion, better adherence, reduced cost). A consequence is that, for a
given power, a larger margin should be associated with some
larger advantages.
Comparison between the two ‘exact’ methods is confusing. First
the difference between these two methods is more important than
between any exact and any non-exact method. Second, the term
‘exact’ may be very confusing for clinicians who consider that an
‘exact’ method is definitive and that no improvement can be
made. In general, one considers that exact methods are better or
more appropriate than non-exact methods. But which exact
method should be used? Chan and Zhang suggested their method
because they pointed out that the SS method was overly
conservative [21]. Few illustrative examples and a simulation
study in a limited number of situations, both based on small
sample size (n#20), showed an improvement of the CZ method
over the SS method [21]. Our results show that even with larger
sample size, confidence intervals based on the SS are very
conservative suggesting the use of the exact CZ method.
Interestingly some authors have suggested that approximate is
better than exact for interval estimation of binomial proportions
[35,36]. So again, which method should be used? A first work
compared three methods (Wald, Dunnett and Gent, FM) for
testing therapeutic equivalence in a clinical setting (n..20) [37].
The authors concluded that both Wald and FM methods can be
used for DL,p2/2. For quite unusual configurations, the Wald
method performed even better [37]. Newcombe provided the
largest investigation of methods for interval estimation for the
difference between two proportions [38]. Eleven methods were
compared in a very large setting covering a wide range of
parameters (p1,p2) but mainly with low sample size (n=5 to 50).
He concluded that the Newcombe method achieved better
coverage probability than any simple methods. Nevertheless, none
of the exact method was included in the comparison. In a last
work, Barker and colleagues compared 8 methods for testing
equivalence in the case of difference of two binomial proportions,
including the Wald and Newcombe methods but not the FM and
CZ or SS exact methods [39]. Surprisingly, the conclusion of their
simulation study did not accurately reflect results shown in their
tables. For example, they concluded that when n1=n 2=50 the
WALD method is not anti-conservative this is true because this
approach is very conservative (cf reference [39], pp281, Table 2
n=50). Those different works highlighted the difficulty to choose a
method although the exact CZ, Newcombe and FM methods
seem the most appropriate.
A limitation of the study is that we did not applied all the
statistical methods that have been proposed to estimate confidence
intervals for the difference between independent proportions. The
four methods, however, where the methods used in HIV
noninferiority trials publisehed in 2010 and represent a large
panel of methods. It can also be argued that each method used for
the analysis was also used for sample size/power determination.
And then only the planned method should be used as
corresponding to a given sample size and power. In fact, the four
methods provide almost similar sample sizes. For example, with
p1=p 2=0.90, a=0.025 (one-sided) 1-b=90%, and DL=0.10,
the sample size per group is 189, 204, 200 and 201 with the Wald,
FM, Newcombe and Exact CZ, respectively, and 441, 441, 445,
and 447, respectively with p1=p 2=0.70 (see also reference [22]).
Of note sample size for the Newcombe method is obtained by
simulation [NQueryAdvisor].
In conclusion, the choice of the statistical methods may lead to
different confidence intervals estimates, especially in trials with low
or moderate samples size. The exact CZ, Newcombe and FM
methods seem the most appropriate methods although further
investigation comparing at least those three methods in a clinical
trials setting will be helpful to determine the best method
according to different scenario. Choice of the methods has low
or no impact on determination of the sample size.
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